Navigation Links
Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows
Date:7/27/2010

By Steven Reinberg
HealthDay Reporter

MONDAY, July 26 (HealthDay News) -- Too many men with low-risk prostate cancers, those whose level of prostate-specific antigen (PSA) is normal or below normal, still receive aggressive treatment, a new study shows.

Recent evidence has shown that among older men with low-risk prostate cancer, it's not the cancer they die from, but another condition. For these men, watchful waiting is probably better than surgery or radiation therapy, the researchers noted.

"The difficulty we have right now is that we need further efforts in research to understand who is who, and individualize treatment in a better way," said lead researcher Dr. Robert S. DiPaola, director of the Cancer Institute of New Jersey and associate dean for oncology programs and professor of medicine at UMDNJ-Robert Wood Johnson Medical School in New Brunswick, N.J.

Understanding more about prostate cancer will enable doctors to make better use of the therapies available, he added. "Obviously, there is a large population, if we knew who they were, [that] would not need that therapy," he said.

But on an individual basis, the decision whether to have aggressive treatment or not is complex, DiPaola noted. Because the decision may be different "depending on age, aggressiveness of the tumor, the PSA level, this is a call to action that patients need a very informed discussion. They need all those things considered, and the approach needs to be individualized," he said.

The report is published in the July 26 issue of the Archives of Internal Medicine.

For the study, DiPaola's team collected data on 123,934 men with prostate cancer who were listed in the Surveillance, Epidemiology and End Results (SEER) system. Among these men, 14 percent had PSA levels at or below 4 nanograms per milliliter, which is normal or below normal. These patients were likely to have low-risk cancer, the researchers say.

Although the men had low-risk cancer, more than 75 percent of them underwent surgery to remove their prostate or had radiation therapy, DiPaola's group found.

More than 90 percent of prostate cancers are found before the disease has spread to other parts of the body, and these men have a five-year survival rate of almost 100 percent, the researchers say. Since 1975, the overall survival rate of men with prostate cancer has increased, from 69 percent to almost 99 percent in 2003, they added.

Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said one problem with this study is that whether patients had another serious medical condition, other than prostate cancer, such as heart disease or diabetes, is not mentioned.

"What needs to be done is to look at people's risk profile, not just based on the PSA and the kind of cancer that was diagnosed, but also based on their overall health," he said. "There is no data, to date, to understand the natural history of untreated low-risk, low-PSA, prostate cancer in healthy men in their 60s and 70s whose life expectancy is exceeding 10 to 15 years," he said.

D'Amico thinks that healthy younger men with low-risk prostate cancer may opt for aggressive treatment, while older men in poorer health could benefit from active monitoring. "For men 60 and 65 in good health, I think, treatment is warranted," he said.

For another expert, the problem of overtreatment starts with over-screening.

Dr. Otis Brawley, chief medical officer of the American Cancer Society, said that "there are huge problems with PSA screening." Most men who have prostate cancer will die from some other condition and do not have to have their prostate cancer treated, he added.

"PSA screening is so good it diagnoses far too many men with prostate cancer, and is so bad it misses a lot of prostate cancer," he added.

There are a lot of uncertainties regarding prostate cancer and prostate cancer screening as to whether it save lives, as to whether it diagnoses the cancers that need to be treated or the cancers that simply need to be watched, Brawley said. "Unfortunately, over the last 20 years men have not been told that truth."

Brawley thinks men who are worried about prostate cancer should be screened. "It's okay to get prostate cancer screening, but realize that prostate cancer screening is not nearly as good, as clearly beneficial, as many people have said," he said.

The overdiagnosis of prostate cancer is leading to overtreatment, Brawley said. "Over the last 20 years, since we started screening, well over 2 million men were needlessly treated for prostate cancer," he said.

"At least 40 percent, or probably more than 60 percent of the men who we diagnose, don't need to be diagnosed," Brawley said.

More information

For more information on prostate cancer, visit the American Cancer Society.

SOURCES: Robert S. DiPaola, M.D., director, The Cancer Institute of New Jersey; associate dean, oncology programs, and professor, medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N.J.; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; Otis Brawley, M.D., chief medical officer, American Cancer Society; July 26, 2010, Archives of Internal Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. What is the role of focal therapy in low-risk prostate cancer?
2. Value of Monitoring Low-Risk Prostate Cancer Assessed
3. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
4. Surveillance may be suitable treatment option for patients with low-risk prostate cancer
5. Most men with low-risk prostate cancer receive aggressive treatment
6. Advance Toward Test for Aggressive Prostate Cancer
7. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
8. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
9. Few differences in outcomes between open and laparoscopic prostate surgery
10. Two Surgical Methods Equally Successful for Prostate Cancer
11. Genetic Mutation Linked to Prostate Cancer in Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: